

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Regenerative Medicine International Limited
中國再生醫學國際有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8158)

**(1) DELAY IN PUBLICATION OF AUDITED
ANNUAL RESULTS ANNOUNCEMENT AND
ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2021;
(2) PUBLICATION OF UNAUDITED
ANNUAL RESULTS ANNOUNCEMENT
FOR THE YEAR ENDED 31 DECEMBER 2021;
AND
(3) DATE OF BOARD MEETING**

This announcement is made by China Regenerative Medicine International Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities (the “**GEM Listing Rules**”) on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS ANNOUNCEMENT AND ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Under Rules 18.48A and 18.49 of the GEM Listing Rules, the Company was required to publish the announcement in relation to the preliminary audited annual results of the Group for the year ended 31 December 2021 (the “**2021 Audited Annual Results**”) on a date no later than three months after the end of the financial year of the Company, i.e. on or before 31 March 2022, and despatch its annual report (the “**2021 Annual Report**”) to the shareholders of the Company (the “**Shareholders**”) on or before 31 March 2022. However, a number of factors has caused the delay of audit work of the 2021 Audited annual Results; (i) implementation of the tightened COVID-19 prevention and control quarantine measures in the Peoples’s Republic of China (the “**PRC**”) and Hong Kong in the past few weeks; (ii) delays in receiving audit confirmation from banks resulting from limited services within the PRC and Hong Kong; and (iii) employees of the Company’s auditor (the “**Auditor**”) were tested positive for COVID-19, which affected the ability to access and gather necessary documents and information required for audit on a timely basis.

In view of the above, the board (the “**Board**”) of directors (the “**Directors**”) of the Company would like to inform the Shareholders and potential investors of the Company that it is unlikely that the Company will be able to publish the 2021 Audited Annual Results and despatch the 2021 Annual Report on or before 31 March 2022 in accordance with the GEM Listing Rules. Notwithstanding this, the Board would like to emphasize that the operation of the Group remains normal and that it will continue to work with the auditor of the Company closely to publish the 2021 Annual Results and despatch of the 2021 Annual Report to the Shareholders. The 2021 Annual Results and the 2021 Annual Report are expected to be published by the end of April 2022.

PUBLICATION OF UNAUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021

To ensure that the Shareholders and potential investors of the Company are informed of the Group's business operation and financial position, the Board has decided to publish the unaudited annual results announcement of the Group for the year ended 31 December 2021 (the “**2021 Unaudited Annual Results Announcement**”) on 31 March 2022.

The Board will review and approve, among other things, the publication of the 2021 Unaudited Annual Results (the “**2021 Unaudited Annual Results**”) based on the management accounts of the Group for the year ended 31 December 2021.

DATE OF BOARD MEETING

The Board hereby announces that, a meeting of the Board will be held on Thursday, 31 March 2022 for the purpose of, among other matters, considering and approving the 2021 Unaudited Annual Results and its publication, and considering the recommendation on the payment of a final dividend, if any, and transacting any other business.

The Company will make further announcement(s) as and when appropriate in relation to the latest development of the audit processes and the expected date of publishing the 2021 Audited Annual Results and the 2021 Annual Report. The Company will publish the 2021 Audited Annual Results and the 2021 Annual Report in compliance with the GEM Listing Rules as soon as practicable.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board

China Regenerative Medicine International Limited

Wang Chuang

Chairman, Chief Executive Officer and Executive Director

Hong Kong, 25 March 2022

As at the date of this announcement, the executive Director is Mr. Wang Chuang (Chairman and Chief Executive Officer); the non-executive Director is Mr. Tsang Ho Yin; and the independent non-executive Directors are Dr. Liu Ming, Ms. Huo Chunyu and Mr. Leung Man Fai.

This announcement, for which the Directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for at least seven days from the date of the publication and will be published on the website of the Company at www.crmi.hk.